# A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

> **NCT03428100** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 463 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo
- **DRUG:** Topical corticosteroid

## Key facts

- **NCT ID:** NCT03428100
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2019-11-25
- **Final completion:** 2023-04-20
- **Target enrollment:** 463 (ACTUAL)
- **Last updated:** 2024-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03428100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03428100, "A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03428100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*